Virax Biolabs Group Ltd
VRAX0.370USD
+0.020+5.69%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.42MMarket Cap
LossP/E TTM
More Details of Virax Biolabs Group Ltd Company
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Virax Biolabs Group Ltd Info
Ticker SymbolVRAX
Company nameVirax Biolabs Group Ltd
IPO dateJul 14, 2022
CEOFoster (James)
Number of employees19
Security typeOrdinary Share
Fiscal year-endJul 14
AddressBiocity Glasgow
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeML1 5UH
Phone4402077887414
Websitehttps://www.viraxbiolabs.com
Ticker SymbolVRAX
IPO dateJul 14, 2022
CEOFoster (James)
Company Executives of Virax Biolabs Group Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
287.99K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
287.99K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foster (James)
4.40%
Armistice Capital LLC
3.49%
HRT Financial LP
0.92%
Mccracken (Nigel Ph.D.)
0.36%
Virtu Americas LLC
0.33%
Other
90.51%
Shareholders
Shareholders
Proportion
Foster (James)
4.40%
Armistice Capital LLC
3.49%
HRT Financial LP
0.92%
Mccracken (Nigel Ph.D.)
0.36%
Virtu Americas LLC
0.33%
Other
90.51%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.00%
Hedge Fund
5.25%
Investment Advisor
1.00%
Research Firm
0.49%
Bank and Trust
0.23%
Other
87.03%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
22
263.22K
6.06%
-53.31K
2025Q2
26
729.04K
16.79%
+148.45K
2025Q1
23
579.67K
13.35%
-10.90K
2024Q4
24
579.58K
13.35%
-22.54K
2024Q3
22
734.94K
16.93%
+329.85K
2024Q2
22
359.31K
9.40%
-99.69K
2024Q1
20
305.99K
7.33%
-151.07K
2023Q4
20
422.04K
26.02%
+96.63K
2023Q3
24
636.78K
40.92%
-179.86K
2023Q2
22
639.17K
41.06%
-174.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foster (James)
368.57K
8.49%
+80.58K
+27.98%
Mar 31, 2025
Armistice Capital LLC
228.04K
5.25%
+228.04K
--
Sep 30, 2024
HRT Financial LP
--
0%
-13.51K
-100.00%
Jun 30, 2025
Mccracken (Nigel Ph.D.)
23.33K
0.54%
+23.33K
--
Mar 31, 2025
Virtu Americas LLC
--
0%
-28.06K
-100.00%
Sep 30, 2024
Norton (Evan)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Erez (Yair)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Haight (Nelson)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
National Bank of Canada
5.00K
0.12%
+5.00K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Date
Type
Ratio
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
FAQs
Who are the top five shareholders of Virax Biolabs Group Ltd?
The top five shareholders of Virax Biolabs Group Ltd are:
Foster (James) holds 368.57K shares, accounting for 8.49% of the total shares.
Armistice Capital LLC holds 228.04K shares, accounting for 5.25% of the total shares.
HRT Financial LP holds 0.00 shares, accounting for 0.00% of the total shares.
Mccracken (Nigel Ph.D.) holds 23.33K shares, accounting for 0.54% of the total shares.
Virtu Americas LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Foster (James) holds 368.57K shares, accounting for 8.49% of the total shares.
Armistice Capital LLC holds 228.04K shares, accounting for 5.25% of the total shares.
HRT Financial LP holds 0.00 shares, accounting for 0.00% of the total shares.
Mccracken (Nigel Ph.D.) holds 23.33K shares, accounting for 0.54% of the total shares.
Virtu Americas LLC holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Virax Biolabs Group Ltd?
The top three shareholder types of Virax Biolabs Group Ltd are:
Foster (James)
Armistice Capital LLC
HRT Financial LP
Foster (James)
Armistice Capital LLC
HRT Financial LP
How many institutions hold shares of Virax Biolabs Group Ltd (VRAX)?
As of 2025Q3, 22 institutions hold shares of Virax Biolabs Group Ltd, with a combined market value of approximately 263.22K, accounting for 6.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.73%.
What is the biggest source of revenue for Virax Biolabs Group Ltd?
In --, the -- business generated the highest revenue for Virax Biolabs Group Ltd, amounting to -- and accounting for --% of total revenue.
